Glioblastoma recurrence correlates with NLGN3 levels. (18th May 2018)

• Record Type: Journal Article
• Authors: Liu, Rui; Qin, Xing‐Ping; Zhuang, Yang; Zhang, Ya; Liao, Hua‐Bao; Tang, Jun‐Chun; Pan, Meng‐Xian; Zeng, Fei‐Fei; Lei, Yang; Lei, Rui‐Xue; Wang, Shu; Liu, An‐Chun; Chen, Juan; Zhang, Zhi‐Feng; Zhao, Dan; Wu, Song‐Lin; Liu, Ren‐Zhong; Wang, Ze‐Fen; Wan, Qi
• Is Part Of: Cancer medicine. Volume 7:Number 7(2018:Jul.)
• Page Start: 2848
• Page End: 2859
• Publication Date: 2018-05-18
• Subjects: ADAM10 inhibitor -- deep brain region -- glioblastoma -- NLGN3 -- recurrence; 616.994005
• DOI: 10.1002/cam4.1538
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Glioblastoma (GBM) is the most aggressive glioma in the brain. Recurrence of GBM is almost inevitable within a short term after tumor resection. In a retrospective study of 386 cases of GBM collected between 2013 and 2016, we found that recurrence of GBM mainly occurs in the deep brain regions, including the basal ganglia, thalamus, and corpus callosum. But the mechanism underlying this phenomenon is not clear. Previous studies suggest that neuroligin‐3 (NLGN3) is necessary for GBM growth. Our results show that the levels of NLGN3 in the cortex are higher than those in the deep regions in a normal human brain, and similar patterns are also found in a normal mouse brain. In contrast, NLGN3 levels in the deep brain regions of GBM patients are high. We also show that an increase in NLGN3 concentration promotes the growth of U251 cells and U87‐MG cells. Respective use of the cortex neuron culture medium (C‐NCM) and basal ganglia neuron culture medium (BG‐NCM) with DMEM to cultivate U251, U87‐MG and GBM cells isolated from patients, we found that these cells grew faster after treatment with C‐NCM and BG‐NCM in which the cells treated with C‐NCM grew faster than the ones treated with BG‐NCM group. Inhibition of NLGN3 release by ADAM10i prevents NCM‐induced cell growth. Together, this study suggests that increased levels of NLGN3 in the deep brain region under the GBM pathological circumstances may contribute to GBM recurrence in the basal ganglia, thalamus, and corpus callosum. Abstract : This study suggests that increased level of neuroligin‐3 in the deep brain region under the pathological circumstances may contribute to GBM recurrence in the basal ganglia, thalamus, and corpus callosum.